Nevirapine

證據等級: L5

預測適應症: 10 個

Nevirapine: From HIV-1 Antiretroviral Therapy to Prevention of Mother-to-Child HIV Transmission

One-Sentence Summary

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) established for HIV-1 antiretroviral therapy, currently not registered in the Australian ARTG. Of the ten TxGNN-predicted indications reviewed for this drug, most top-scoring candidates (feline immunodeficiency virus, simian immunodeficiency virus, a rare neurodevelopmental disorder, and several benign tumours) have no human clinical relevance and are flagged “Hold” in the evidence pack itself. The best-supported candidate — extending nevirapine’s established mechanism to prevention of mother-to-child (perinatal) HIV transmission, i.e. congenital HIV — is backed by 10+ completed Phase 3 trials and 20 publications, reflecting decades of real-world perinatal use rather than a genuinely novel repurposing hypothesis.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (antiretroviral therapy) — not listed in an Australian ARTG entry; known internationally as an approved NNRTI
Predicted New Indication	Prevention of Mother-to-Child (Perinatal) HIV Transmission — Congenital HIV
TxGNN Prediction Score	98.52%
Evidence Level	L1
Australia Market Status	Not Marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Structured mechanism-of-action data was not available from the evidence pack (original_moa: [Data Gap]). However, the literature evidence retrieved for this candidate repeatedly and consistently describes nevirapine as a first-generation NNRTI: it binds non-competitively at a hydrophobic pocket adjacent to the active site of HIV-1 reverse transcriptase, blocking the enzyme’s RNA-dependent DNA polymerase activity and halting conversion of viral RNA into proviral DNA.

The predicted “new” indication — congenital HIV / mother-to-child transmission prevention (PMTCT) — is mechanistically identical to nevirapine’s original antiretroviral use, not a distinct pathway. Blocking reverse transcription in the mother reduces maternal viral load, and prophylactic dosing of the neonate blocks establishment of infection during intrapartum and early postnatal exposure. Because nevirapine is orally bioavailable, inexpensive, and has a long half-life permitting single-dose or short-course prophylaxis, it became a WHO-recommended PMTCT strategy in resource-limited settings (e.g., the HIVNET 012 regimen) — this is why the supporting evidence base is unusually large and mature compared with a typical TxGNN-only prediction.

By contrast, the raw top-ranked TxGNN predictions for this drug (feline AIDS, simian immunodeficiency virus infection, an ultra-rare neurodevelopmental disorder, prostate fibroma, Brenner tumour) either concern non-human disease models or benign neoplasms with no plausible link to an antiretroviral mechanism — the evidence pack’s own rationale text flags these as likely graph noise, and this report does not pursue them further.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00001135	Phase 3	Completed	2,009	Double-blind RCT of nevirapine (NVP) given to mother and infant vs. control to reduce maternal-fetal HIV transmission
NCT00639938	Phase 3	Completed	722	Standard two-dose NVP regimen ± HIV immune globulin or extended infant NVP dosing for PMTCT in Uganda
NCT01061151	Phase 3	Completed	3,747	PROMISE study — optimal antepartum, intrapartum and breastfeeding-period PMTCT interventions
NCT02738502	Phase 2	Completed	91	PMTCT strategy without NRTIs; neonatal prophylaxis with nevirapine
NCT03642704	Phase 4	Completed	56	Early HIV diagnosis and preventive antiretroviral treatment (incl. NVP) at birth for high-risk newborns, Guinea
NCT01511237	Phase 3	Completed	379	PHPT-5 — perinatal antiretroviral intensification for PMTCT in women with <8 weeks antenatal HAART, Thailand
NCT00164736	Phase 3	Completed	2,369	ARV prophylaxis (mother or infant) plus nutritional support to prevent transmission during breastfeeding
NCT00197587	N/A	Completed	1,200	“Mashi” study — prevention of milk-borne HIV-1C transmission, Botswana
NCT02383849	N/A (Phase 4)	Completed	124	IMPAACT P1106 — pharmacokinetics and safety of nevirapine (and other ARVs) in low-birth-weight infants
NCT00102960	Phase 3	Completed	377	Strategies for antiretroviral therapy in infants shortly after primary HIV infection, resource-poor setting

No ANZCTR-registered trials were identified for this indication in the evidence pack.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15249569	2004	RCT	JAMA	Nevirapine + zidovudine given at birth reduces perinatal HIV transmission in women presenting in labour with unknown HIV status
29912896	2018	Systematic review / NMA	PLoS ONE	Network meta-analysis of comparative safety/effectiveness of perinatal antiretroviral regimens
19236121	2009	Systematic review	Drug Safety	Hepatotoxicity risk with long- vs short-course prophylactic nevirapine use (RADAR project)
11825335	2001	Review	Expert Opin Pharmacother	Overview of nevirapine’s role and efficacy in HIV-1 treatment
15794723	2005	Review	Expert Opin Drug Saf	Safety of antiretroviral drugs, incl. nevirapine, in pregnancy
21711178	2011	Cohort	AIDS Care	Maternal HIV infection and birth outcomes under enhanced antenatal PMTCT care, Pune, India
24781315	2014	Cohort	PLoS Medicine	French ANRS perinatal cohort — birth defect prevalence by individual ARV drug exposure
21084995	2011	Cohort	J Acquir Immune Defic Syndr	Pregnancy outcomes compared between efavirenz- and nevirapine-exposed women
35621877	2022	Cohort	J Acquir Immune Defic Syndr	Impact of antenatal ARV regimen on pregnancy/infant outcomes in HIV/HBV coinfection
17713983	2007	Cohort	PLoS Medicine	Two-tiered PMTCT strategy evaluation, West Africa

Safety Considerations

Structured safety fields (key warnings, contraindications, DDI) were not available for this candidate. However, literature evidence retrieved for this indication repeatedly flags hepatotoxicity and severe cutaneous reactions as characteristic nevirapine risks — including a systematic review/meta-analysis specifically on short- vs. long-course prophylactic use (PMID 19236121) and a toxicogenomics study of cutaneous/hepatic adverse events across populations (PMID 21505298). As nevirapine is not currently registered in Australia, prescribers should obtain formal safety and interaction data from the TGA-approved Product Information once available, rather than relying on this evidence summary alone.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 3 RCTs and a large observational/systematic-review literature base (L1) support nevirapine’s use in perinatal HIV transmission prevention — but this is an extension of its existing, decades-old antiretroviral mechanism rather than a novel repurposing signal, and the drug is currently unregistered in Australia (0 ARTG entries).

To proceed, the following is needed:

TFDA/TGA product information — warnings and contraindications (currently a Blocking data gap; required before any S1 safety assessment)
Formal DrugBank/PI-sourced mechanism-of-action confirmation (currently a High-severity data gap)
Australian regulatory pathway assessment for ARTG registration, given current “not marketed” status
A structured drug-drug interaction query (current DDI query returned “not found”)
Australian-context perinatal/neonatal dosing guidance if pursued for a PMTCT program
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.